Welcome to our dedicated page for Glycomimetics news (Ticker: GLYC), a resource for investors and traders seeking the latest updates and insights on Glycomimetics stock.
GlycoMimetics, Inc. develops glycobiology-based therapies for cancers, including acute myeloid leukemia, and inflammatory diseases. Its platform uses specialized chemistry to discover small molecule glycomimetics that alter carbohydrate-mediated cell recognition.
Company news centers on uproleselan clinical data in AML, presentations of trial results, regulatory-path updates, and pipeline references including GMI-1687. Recurring corporate developments also include material agreements, shareholder voting matters, capital-structure disclosures, governance updates, strategic review and restructuring activity, and operating and financial results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
GlycoMimetics, Inc. (Nasdaq: GLYC) has announced a conference call scheduled for May 3, 2023, at 8:30 a.m. ET to discuss its first quarter 2023 financial results. Investors can participate by registering through a provided link to receive dial-in details, with a reminder to connect 15 minutes early.
The company is a late clinical-stage biotechnology firm focused on developing therapies for cancers like AML and inflammatory diseases. Its innovative research is based on glycobiology, emphasizing carbohydrate interactions in cell recognition to create glycomimetics aimed at addressing significant medical needs.
GlycoMimetics announced significant advancements in leadership and capital raising as it prepares for the final results of its Phase 3 study on uproleselan in treating relapsed/refractory acute myeloid leukemia (AML). The independent Data Monitoring Committee (DMC) endorsed the continuation of the trial after a high statistical interim analysis, expecting final survival events by mid-2024. Financially, GlycoMimetics reported cash and equivalents of $47.9 million as of December 31, 2022, and raised an additional $28.7 million post-year-end. R&D expenses dropped to $28.4 million for 2022, while overall revenue remained minimal at $1.2 million, attributed to licensing collaborations.